How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Pharma & Biotech
Pharma & Biotech
Alnylam Pharmaceuticals taps Tenaya Therapeutics to uncover new cardiovascular RNAi drug targets
Alnylam Pharmaceuticals partners with Tenaya Therapeutics to discover RNAi targets for cardiovascular disease. Read the analysis behind this biotech collaboration.